- Report
- April 2025
- 175 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Report
- March 2025
- 250 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Report
- February 2025
- 200 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Clinical Trials
- April 2025
- 85 Pages
Global
From €1757EUR$2,000USD£1,516GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1318EUR$1,500USD£1,137GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2451EUR$2,789USD£2,114GBP
- Report
- November 2022
- 154 Pages
Global
From €4393EUR$5,000USD£3,790GBP
- Report
- June 2020
- 753 Pages
Global
From €2900EUR$3,300USD£2,501GBP
- Report
- July 2025
- 50 Pages
Global
From €2328EUR$2,650USD£2,009GBP
Nilotinib is an oncology drug used to treat certain types of leukemia. It is a tyrosine kinase inhibitor, which works by blocking the activity of certain enzymes that are involved in the growth and spread of cancer cells. Nilotinib is used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is also used to treat CML in patients who have already been treated with other drugs.
Nilotinib is available in both capsule and oral solution form. It is usually taken twice a day, with or without food. Common side effects include nausea, vomiting, diarrhea, muscle pain, and fatigue.
Nilotinib is marketed by Novartis, Pfizer, and Sun Pharmaceuticals. It is also available in generic form from several other manufacturers. Show Less Read more
